Bavarian Nordic is highly specialized
in the research, development and manufacturing of vaccines based on
viral vectors for the delivery of antigens targeting infectious
diseases and cancers.
The Company has developed its
proprietary MVA-BN® technology and established a manufacturing
infrastructure and competencies to produce MVA-BN® vaccines at
a commercial scale.
Through the in-licensing of other
technologies, the Company continues to build expertise in viral
vector-based vaccines in order to enhance and further develop other
emerging technologies such as VF-TRICOM, which in clinical trials
has demonstrated potential clinical benefit, was well-tolerated and
offered the advantage of ease of administration.
Our core competences are:
